David Delaney files SEC Form 4 disclosures for Pasithea Therapeutics Corp.. They have made 1 open-market trade across 1 company since 2022, most recently 2022-10-17.
CIK 0001943013
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
1 open-market purchase totalling $1K since 2022, never a sale. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| KTTA | 227,521 | $97K |
Shares reported on the most recent Form 4, priced at the 2022-10-19 close.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| KTTA | BUY | 2022-10-17 | 2022-10-19 | $1.11 | $1K | -1.7% | -5.5% | -35.1% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.